Terms: = Sarcomas AND ESR1, ESR, 2099, ENSG00000091831, RP1-130E4_1, NR3A1, ESRA, DKFZp686N23123, ER, Era AND Clinical Outcome
432 results:
1. Tumours of the foot: A 10 years retrospective analysis.
Ajit Singh V; Sandhu V; Tze Yong C; Yasin NF
J Orthop Surg (Hong Kong); 2024; 32(1):10225536241248706. PubMed ID: 38662594
[TBL] [Abstract] [Full Text] [Related]
2. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
Recio F; Scalise CB; Loar P; Lumish M; Berman T; Peddada A; Kalashnikova E; Rivero-Hinojosa S; Beisch T; Nicosia B; Farmer T; Dutta P; Malhotra M; ElNaggar AC; Liu MC; Vaccarello L; Holloway RW
Gynecol Oncol; 2024 Mar; 182():63-69. PubMed ID: 38262240
[TBL] [Abstract] [Full Text] [Related]
3. [clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
[No Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcome in Patients With High-grade Soft-tissue Sarcoma Receiving Prosthetic Replacement After Tumor Resection of the Lower Extremities: Tokai Musculoskeletal Oncology Consortium Study.
Nakamura T; Sakai T; Tsukushi S; Kimura H; Wasa J; Hosono K; Izubuchi Y; Kozawa E; Nagano A; Asanuma K; Sudo A; Nishida Y
In Vivo; 2023; 37(6):2642-2647. PubMed ID: 37905645
[TBL] [Abstract] [Full Text] [Related]
6. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract] [Full Text] [Related]
7. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Martin-Broto J; Valverde C; Hindi N; Vincenzi B; Martinez-Trufero J; Grignani G; Italiano A; Lavernia J; Vallejo A; Tos PD; Le Loarer F; Gonzalez-Campora R; Ramos R; Hernández-Jover D; Gutierrez A; Serrano C; Monteagudo M; Letón R; Robledo M; Moura DS; Martin-Ruiz M; López-Guerrero JA; Cruz J; Fernandez-Serra A; Blay JY; Fumagalli E; Martinez-Marin V
Mol Cancer; 2023 Aug; 22(1):127. PubMed ID: 37559050
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
[TBL] [Abstract] [Full Text] [Related]
9. clinical outcomes of Intensity-modulated Carbon-ion Radiotherapy for Bone and Soft Tissue Tumors.
Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
Anticancer Res; 2023 Jun; 43(6):2777-2781. PubMed ID: 37247930
[TBL] [Abstract] [Full Text] [Related]
10. Type 2 Diabetes Mellitus and Efficacy outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Cortellini A; D'Alessio A; Cleary S; Buti S; Bersanelli M; Bordi P; Tonini G; Vincenzi B; Tucci M; Russo A; Pantano F; Russano M; Stucci LS; Sergi MC; Falconi M; Zarzana MA; Santini D; Spagnolo F; Tanda ET; Rastelli F; Giorgi FC; Pergolesi F; Giusti R; Filetti M; Lo Bianco F; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; Grossi F; De Tursi M; Di Marino P; Queirolo P; Bracarda S; Macrini S; Inno A; Zoratto F; Veltri E; Spoto C; Vitale MG; Cannita K; Gennari A; Morganstein DL; Mallardo D; Nibid L; Sabarese G; Brunetti L; Perrone G; Ascierto PA; Ficorella C; Pinato DJ
Clin Cancer Res; 2023 Jul; 29(14):2714-2724. PubMed ID: 37125965
[TBL] [Abstract] [Full Text] [Related]
11. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
12. Neurosurgical management of proton beam therapy-induced moyamoya syndrome.
Zhang CH; Muirhead W; Silva AHD; Toolis C; Robertson F; Rennie A; Bhate S; Thompson DNP; Ganesan V; James G
J Neurosurg Pediatr; 2023 Apr; 31(4):369-379. PubMed ID: 36738468
[TBL] [Abstract] [Full Text] [Related]
13. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
[TBL] [Abstract] [Full Text] [Related]
14. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with clinical outcome and Are Detectable in Cell-Free DNA.
Cortes-Ciriano I; Steele CD; Piculell K; Al-Ibraheemi A; Eulo V; Bui MM; Chatzipli A; Dickson BC; Borcherding DC; Feber A; Galor A; Hart J; Jones KB; Jordan JT; Kim RH; Lindsay D; Miller C; Nishida Y; Proszek PZ; Serrano J; Sundby RT; Szymanski JJ; Ullrich NJ; Viskochil D; Wang X; Snuderl M; Park PJ; Flanagan AM; Hirbe AC; Pillay N; Miller DT;
Cancer Discov; 2023 Mar; 13(3):654-671. PubMed ID: 36598417
[TBL] [Abstract] [Full Text] [Related]
15. Novel reconstruction method by mega-prosthesis wrapped with vancomycin-containing cement after resection of malignancies.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M
Medicine (Baltimore); 2022 Dec; 101(48):e31547. PubMed ID: 36482578
[TBL] [Abstract] [Full Text] [Related]
16. Extraskeletal myxoid chondrosarcoma: p53 and Ki-67 offer prognostic value for clinical outcome - an immunohistochemical and molecular analysis of 31 cases.
Giner F; López-Guerrero JA; Machado I; Rubio-Martínez LA; Espino M; Navarro S; Agra-Pujol C; Ferrández A; Llombart-Bosch A
Virchows Arch; 2023 Feb; 482(2):407-417. PubMed ID: 36376703
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
18. clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis.
Varey AHR; Williams GJ; Lo SN; Taing CY; Maurichi A; Santinami M; Scolyer RA; Thompson JF
J Eur Acad Dermatol Venereol; 2023 May; 37(5):859-870. PubMed ID: 36251355
[TBL] [Abstract] [Full Text] [Related]
19. CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma.
Brunac AC; Fourquet J; Perot G; Jaffrelot M; Meilleroux J; Danjoux M; Filleron T; Nicolaï V; Guimbaud R; Icher S; Farés N; Selves J; Chibon F
Mod Pathol; 2022 Dec; 35(12):2002-2010. PubMed ID: 36202996
[TBL] [Abstract] [Full Text] [Related]
20. Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.
Yang J; Li W; Feng R; Li D
BMC Musculoskelet Disord; 2022 Sep; 23(1):890. PubMed ID: 36180843
[TBL] [Abstract] [Full Text] [Related]
[Next]
